ADHD Drug Zenzedi Recalled Over Pill Mixup
30 Jan 2024
TUESDAY, Jan. 30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.
The recall notice, issued by Azurity Pharmaceuticals Inc., states that one lot of Zenzedi 30-milligram tablets is being recalled after a pharmacist found antihistamine tablets in a bottle labeled as Zenzedi.
The active compound in Zenzedi is dextroamphetamine sulfate, a stimulant used for the treatment of narcolepsy and ADHD. Meanwhile, the allergy drug found in the mislabeled bottles contains the sedative carbinoxamine, which has the opposite effect of a stimulant.
The recall notice said that people who take carbinoxamine instead of Zenzedi have a higher risk of accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction and thyroid disorder. The recalled lot has the lot number F230169A and an expiration date of June 2025.
Azurity added that it has not received any reports of serious injury related to the medication mixup.
Consumers who have the recalled medication should return it to their pharmacy and call their doctor if they have any bad reactions to the drug.
Problems may also be reported to the FDA’s MedWatch Adverse Event Reporting program.
Sources
U.S. Food and Drug Administration, recall notice, Jan. 25, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.